Education
About Us
Working with TipRanks
Follow Us
Biorestorative Therapies, Inc. (BRTX)
:BRTX
BRTX Stock Chart & Stats
$1.62
-$0.13(-7.22%)
At close: 4:00 PM EST
$1.62
-$0.13(-7.22%)
Day’s Range― - ―
52-Week Range$1.19 - $2.55
Previous CloseN/A
Volume34.37K
Average Volume (3M)63.92K
Market Cap
$13.85M
Enterprise Value$7.19M
Total Cash (Recent Filing)$7.38M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.96
Next Earnings
Nov 18, 2025EPS Estimate
-0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.30
Shares Outstanding8,656,242
10 Day Avg. Volume43,755
30 Day Avg. Volume63,920
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.30
Price to Sales (P/S)27.69
P/FCF Ratio-1.33
Enterprise Value/Market Cap0.52
Enterprise Value/Revenue11.88
Enterprise Value/Gross Profit12.57
Enterprise Value/Ebitda-0.55
Forecast
1Y Price Target
$8.00Price Target Upside393.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Market ExpansionBRTX-100 has received IND clearance to move into a Phase 2 study for cervical spinal pain, potentially expanding its market and application.
Product DifferentiationHypoxic culturing makes BRTX-100 differentiated in cell therapy, offering a unique advantage in the market.
Regulatory ApprovalThe company recently received Fast Track designation from FDA, which could expedite the approval process for its treatments.
Bears Say
Clinical Trial EnrollmentBioRestorative has made further progress with enrollment passing the 1/3rd mark.
BioRestorative Therapies News
BRTX FAQ
What was Biorestorative Therapies, Inc.’s price range in the past 12 months?
Biorestorative Therapies, Inc. lowest stock price was $1.19 and its highest was $2.55 in the past 12 months.
What is Biorestorative Therapies, Inc.’s market cap?
Biorestorative Therapies, Inc.’s market cap is $13.85M.
When is Biorestorative Therapies, Inc.’s upcoming earnings report date?
Biorestorative Therapies, Inc.’s upcoming earnings report date is Nov 18, 2025 which is in 25 days.
How were Biorestorative Therapies, Inc.’s earnings last quarter?
Biorestorative Therapies, Inc. released its earnings results on Aug 12, 2025. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.37 by $0.07.
Is Biorestorative Therapies, Inc. overvalued?
According to Wall Street analysts Biorestorative Therapies, Inc.’s price is currently Undervalued.
Does Biorestorative Therapies, Inc. pay dividends?
Biorestorative Therapies, Inc. does not currently pay dividends.
What is Biorestorative Therapies, Inc.’s EPS estimate?
Biorestorative Therapies, Inc.’s EPS estimate is -0.36.
How many shares outstanding does Biorestorative Therapies, Inc. have?
Biorestorative Therapies, Inc. has 8,656,242 shares outstanding.
What happened to Biorestorative Therapies, Inc.’s price movement after its last earnings report?
Biorestorative Therapies, Inc. reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.37. Following the earnings report the stock price went up 2.041%.
Which hedge fund is a major shareholder of Biorestorative Therapies, Inc.?
Currently, no hedge funds are holding shares in BRTX
Company Description
Biorestorative Therapies, Inc.
BioRestorative Therapies (BRTX) is a biotechnology company focused on the development of innovative therapeutic solutions using cell and tissue therapies. The company operates primarily in the field of regenerative medicine, with a particular emphasis on stem cell-based therapies for the treatment of chronic lumbar disc disease and metabolic disorders. Its core products include BRTX-100, a stem cell-based therapeutic targeting disc/spine disease, and ThermoStem, a program focused on metabolic disorders including obesity and diabetes.
BRTX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant revenue growth and promising clinical trial results, particularly for BRTX-100, alongside a strong financial position with no debt. However, these positives were tempered by an increased operational loss and uncertainty in future revenue projections from the BioCosmeceutical business. On balance, the achievements and progress in clinical trials and regulatory pathways suggest a positive outlook.View all BRTX earnings summariesBRTX Stock 12 Month Forecast
Average Price Target
$8.00
▲(393.83% Upside)
Technical Analysis
Cellectar Biosciences
―
Marker Therapeutics
―
Cocrystal Pharma
―
Sensei Biotherapeutics
―
AEON Biopharma
―
Ownership Overview
14.69% Insiders
0.96% Mutual Funds
1.17% Other Institutional Investors
82.95% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---